Literature DB >> 32741034

Disease burden of viral hepatitis A, B, C and E: A systematic analysis.

Zhenqiu Liu1,2, Oumin Shi3, Tiejun Zhang4,5, Li Jin1,2, Xingdong Chen1,2.   

Abstract

Viral hepatitis has been recognized as a leading cause of deaths worldwide. We aimed to analyse the disease burden of viral hepatitis at the global, regional and national levels. We collected the data of death number, mortality rate, and disability-adjusted life years (DALYs) of viral hepatitis by sex, age, geography and type of disease from the Global Health Data Exchange platform. Estimated average percentage change (EAPC) was used to quantify the age-standardized mortality rate (ASMR) of viral hepatitis between 1990 and 2017. Globally, the number of deaths from viral hepatitis increased from 980.9 thousand in 1990 to 1412.3 thousand in 2017, accompanying by the DALYs increased from 35.2 million to 43.1 million in the same period. Hepatitis B and C accounted for 97.6% of total viral hepatitis-related deaths worldwide in 2017. While the death number and DALYs were decreased in acute hepatitis A, B, C and E, a significant increase was found in liver cancer and cirrhosis due to hepatitis B and C. The ASMRs of liver cancer and cirrhosis caused by hepatitis B and C were decreased at the global level and in most regions. However, a significant increase was observed in several developed countries, such as the USA and the UK. The disease burden of viral hepatitis continues to increase worldwide, which was driven by the increase in burden of chronic hepatitis B and C.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  DALYs; disease burden; mortality; viral hepatitis

Year:  2020        PMID: 32741034     DOI: 10.1111/jvh.13371

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  4 in total

1.  The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels.

Authors:  Jianqing Yang; Guangdong Pan; Linjing Guan; Zhipeng Liu; Yongrong Wu; Zhen Liu; Wuchang Lu; Shuai Li; Honglai Xu; Guoqing Ouyang
Journal:  Cancer Med       Date:  2022-01-06       Impact factor: 4.452

Review 2.  Mitochondrial Dysfunction and Chronic Liver Disease.

Authors:  Chunyan Zhang; Yabin Zhao; Mengli Yu; Jianru Qin; Bingyu Ye; Qiwen Wang
Journal:  Curr Issues Mol Biol       Date:  2022-07-09       Impact factor: 2.976

3.  Trend in the incidence of hepatitis A in mainland China from 2004 to 2017: a joinpoint regression analysis.

Authors:  Yuan-Sheng Li; Bei-Bei Zhang; Xi Zhang; Ya-Mei Luo; Jun-Hui Zhang; Song Fan; Li-Ping Fei; Chao Yang; Ning-Jun Ren; Xiang Li
Journal:  BMC Infect Dis       Date:  2022-08-01       Impact factor: 3.667

Review 4.  Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment.

Authors:  Marion Migueres; Sébastien Lhomme; Jacques Izopet
Journal:  Viruses       Date:  2021-09-22       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.